PHP149 Perception of Pharmaceutical Companies on the Drug Price-Volume Negotiation in South Korea  by Kim, E.S. et al.
58 schemes that included a coverage with evidence development component, 25
that included a conditional treatment continuation component, 35 that included a
performance-linked reimbursement component, and 37 that included a patient
level financial utilization component. Each type of scheme addresses fundamental
uncertainties that exist when products enter the market. There has been a contin-
ued upward trend in terms of total schemes adopted per year and the number of
countries with performance-based schemes in place. Despite the continued enthu-
siasm, challenges persist including those related to: 1) the cost and burden of
implementation; 2) the need for consistent processes for scheme development,
data collection, reporting, and evaluation; and 3) negotiating follow-on agreements
after scheme initiation. Furthermore, the challenges faced differ by country, health
system, and product. CONCLUSIONS: There is continued enthusiasm in many
countries for using performance-based schemes for new medical products. Given
the interest to date and the potential to meet the goals of interested stakeholders,
these schemes may become a common element in health care coverage and reim-
bursement. However, significant challenges persist, and future studies are needed
regarding the attitudes and perceptions of various stakeholders as well as evalu-
ating the results and experiences with the schemes implemented thus far.
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OBJECTIVES: To determine whether stakeholders’ opinions on market access is-
sues, in particular the need for QALYs, and risk-sharing, differ by sector and geo-
graphical location.METHODS: A self-completion questionnaire was presented to a
cross section of delegates at the 13th European ISPOR Conference 2010. The ques-
tionnaire comprised 7 items, with both ordinal-polytomous Likert scales and open
ended responses. Analyses were performed to discriminate between the stake-
holder groups including Pearson Chi-squared test of independence, cross-tabula-
tions, and other descriptive statistics for nominal categorical data. The level of
agreement between responder groups was obtained from Cohen’s Kappa coeffi-
cients and radar plots. RESULTS: Respondents included representatives of over 60
companies and organisations from over 30 countries. Highly significantly different
responses were observed between members from European and non-European
countries, with the greatest overall level of agreement being between the industry
and academic sectors (87.5%, K0.75). Fewer respondents from European countries
favoured the use of the QALY than those from non-European countries (31.8% vs.
69.2%), whilst significantly more academics favoured the QALY than either indus-
try or agency respondents (62.1% vs 36.6% vs. 21.4% respectively). More academics
felt that manufacturers should offer patient access schemes (PAS) routinely (41.4%
vs. 19.4% vs. 14.3%). Of non-European respondents, 50.0% felt risk sharing should
form part of all health technology assessments compared with only 25% of respon-
dents from European countries. The majority of non-European respondents (53.8%)
expressed the need for manufacturers to provide PAS routinely; only 16.3% of Eu-
ropean respondents agreed. Only 13.3% of respondents from European countries
thought indirect comparisons are a substitute for head-to-head trials, compared
with 38.5% of respondents from non-European countries. No other significant dif-
ferences in opinions on the need for cost-utility analysis or cost-per-QALY thresh-
olds were found. CONCLUSIONS: Opinions on market access related issues differ
significantly between European and non-European ISPOR members, and between
stakeholder groups.
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OBJECTIVES: With payors increasingly looking at ways of cutting pharmaceutical
reimbursement costs, pharmaceutical companies need to consider creative solu-
tions to market access for new compounds. The objective of this research was to
examine the most recent global trends for 2010 and 2011 in pharmaceutical risk-
sharing agreements, which are now a critical part of market access strategies in
many countries. METHODS: Secondary research was conducted examining reim-
bursement decisions around the world, with a special focus on Australia, Belgium,
Canada, China, France, Germany, Hungary, Italy, The Netherlands, New Zealand,
Poland, Spain, UK and United States. This was supplemented by primary research
with payors, government agencies and HTA organisations through interviews in
native languages to understand the role which risk-sharing agreements have – or
have not – played in their respective markets. RESULTS: Forty-five new risk-shar-
ing agreements were found under the period of review (January 2010-May 2011),
nearly double the total for 2009. Of the new agreements, the majority were finance-
based agreements, though there were six new examples of performance-based
agreements. 40% of the new agreements were concluded with the UK’s NICE, whilst
Australia and Italy remain other important markets in this area. However, a signif-
icant number of newer countries are beginning to see these agreements, including
Belgium, Hungary, Poland and New Zealand, and interest is widening in emerging
markets. Around half of the agreements were in the oncology area, but there are
signs that risk-sharing is becoming increasingly prominent in other therapeutic
areas, including blood disease, mental health, pain treatment, immunology, oph-
thalmology and cardiovascular care. CONCLUSIONS: Risk-sharing agreements are
a reality for pharmaceutical companies in many key markets, and need at least to
be considered as an alternative market access strategy in certain therapeutic areas.
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OBJECTIVES: In Korea, although drug price has continuously decreased due to
many price reduction mechanisms, the volume has been increasing. Because this
risen volume is considered a main contributor of increasing pharmaceutical ex-
penditure, the government adopted price-volume negotiation in 2006. This study
attempted to analyze the status of price-volume (PV) negotiation and identify prob-
lems and the solutions to improve the price-volume negotiation. METHODS: The
comprehensive questionnaire was designed based on Korea price negotiation
guideline and validated by three pilot interviewers. It consisted of the status,
awareness, satisfaction, problems/solutions. Pharmaceutical company’s people
involved in market access were interviewed face-to-face. The response rate was
80% (n34). Multinational and local company accounted for 59% and 41%,
respectively. RESULTS: Most important factors for PV negotiation were budget
impact and price from the Korean PV formula. 69% of 16 PV cases were derived from
the price calculated by PV formula and only 42% reached the consensus on budget
impact because of different data sources. Most respondents agreed with the objec-
tive of the risk-sharing system but the overall satisfaction was significantly low, 1.9
out of 5-point scale. Main reasons are unpredictability of selecting PV product,
discreditable NHIC data and non-transparency of the negotiation process. Also,
76.5% of respondents was against PV negotiation because of the government’s
unnecessary intervention and concerns on weakening the pharmaceutical indus-
try. Especially, respondents worried about profit deterioration due to duplicated
price reduction. In response, they suggested the advanced PV model with a more
specific PV inclusion criteria and the choice between price reduction and pay-back.
Additionally, generic promotion and pay-back system activation to contain the
drug expenditure are preferred over price-volume negotiation. CONCLUSIONS:
The price-volume negotiation in Korea must be improved to motivate the pharma-
ceutical industry through adopting their opinions on advanced PV model which
includes pay-back.
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OBJECTIVES: Pharmaceutical pricing decisions are adopted in a context of uncer-
tainty with regard to the efficacy and safety of the drug as well as to their budgetary
implications. Traditionally, pharmaceutical firms have received a fixed price per
unit sold regardless of health outcomes and sales volume. This pricing policy tends
to increase health budgets and may restrict the access to pharmaceutical innova-
tions for patients. Recently, health authorities have begun to use risk-sharing con-
tracts based on health outcomes to cope with the aforementioned problem. In this
paper, we carry out a theoretical modelling of the risk-sharing contracts, empha-
sizing the variables and parameters that are relevant in the relationship between
health authorities and pharmaceutical firms. METHODS: We have elaborated a
theoretical model that describes the interaction between a pharmaceutical firm
and a public health authority using a two-stage game. In the first stage, the health
authority chooses the pricing policy, either paying to the firm for treated patient or
for cured patient, and in the second stage, the firm, given the pricing policy and the
prescribing behaviour of the physicians, selects the price that maximizes its ex-
pected profits. We solve the game by backward induction, using the subgame per-
fect equilibrium as the solution concept. RESULTS: Risk-sharing contracts are not
always optimal in terms of social welfare. Their optimality depends on the param-
eters of the problem, being conditioned by the prescribing behaviour of the physi-
cians, the efficacy of the drug and the monitoring costs. We characterize the para-
metric regions for which each pricing policy is socially optimal. CONCLUSIONS:
Before using risk-sharing contracts, their convenience must be addressed for each
particular case. As a necessary condition, the existence of objective quantitative
health indicators is required. Otherwise, it is difficult to implement the pricing
policy only based on cured patients.
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OBJECTIVES: Managed entries (MEs) are innovative pricing and reimbursement
agreements aiming to share the risk related to the introduction of new, high-cost
drugs between the payer and the manufacturer. This study aims to review evidence
on the impact of MEs on payer, patients, manufacturer, and health care workers
and to analyse emerging trends in managed entries at international level.
METHODS:A systematic literature review (grey and peer-reviewed) was performed
complemented by search of health technology assessment agency’s websites and
selective interviews with decision makers in key European countries. RESULTS:
Evidence exists of improved cost-effectiveness and lower drug price following the
implementation of coverage with evidence development in Sweden. Data from
France shows that price-volume agreements led to rebates totalling around 3% of
the total drugs bill. Evidence from Italy shows that authorization with a risk-shar-
ing agreement was associated with more rapid patient access in comparison to
authorization without such an agreement. It is unclear whether managed entries
A360 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
